Multiple Myeloma: [68Ga]Ga-PentixaFor Imaging Study

We are exploring a new imaging method to see how well it detects multiple myeloma lesions in patients at diagnosis or relapse. This study may help improve the way we monitor and treat this condition.

1-2 years 6-10 visits Efficacy phase (II)No Placebo Investigational Medicines InjectionHematologyOncology

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Gallium (68ga) Edotreotide

Gallium-68 edotreotide is a radiolabeled tracer used in PET scans to locate neuroendocrine tumors that have somatostatin receptors.

What experimental substances are being tested?

Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.

PentixaFor

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...

Hopital Tenon

Nuclear Medecine

Bagnolet, France

Centre Hospitalier Universitaire De Bordeaux

Nuclear Medecine

Canéjan, France

Hopital Huriez

Nuclear Medecine

Loos, France

Sponsor: Centre Hospitalier Universitaire De Nantes

Last updated: Nov 26, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.